Research
Safety pharmacology of acute mescaline administration in healthy participants.
British journal of clinical pharmacology – November 25, 2024
Summary
Mescaline, a naturally occurring psychedelic, shows promise as a safe therapeutic compound when administered in controlled settings. In healthy volunteers, doses up to 800mg produced positive experiences that outweighed negative ones. While moderate increases in heart rate, blood pressure, and body temperature occurred, they remained within safe ranges. Side effects like nausea were dose-dependent, and flashbacks were rare at 2% of sessions.
Abstract
Psychedelics, including mescaline, may serve as novel treatments for depression and anxiety. However, data is scarce on the safety of mescaline. Th...
Survey of Massachusetts peer recovery coaches' attitudes toward the use of psychedelics to treat substance use disorders.
Addict Sci Clin Pract – November 25, 2024
Summary
In Massachusetts, peer recovery coaches - people who help others overcome addiction through shared experiences - are increasingly open to psychedelic treatments for substance use disorders. 85% of surveyed coaches expressed support for psychedelic therapy when traditional methods fall short. Their firsthand experience with addiction recovery makes their positive outlook particularly noteworthy for advancing treatment options.
Abstract
Survey of Massachusetts peer recovery coaches' attitudes toward the use of psychedelics to treat substance use disorders.
Deepening Psychedelic Integration: Exploring Complex Settings, Understanding User's Struggles, and Implementing Safe Interventions.
Curr Top Behav Neurosci – November 24, 2024
Summary
Navigating psychedelic experiences can be challenging, particularly outside structured environments. New insights reveal that understanding individual struggles is key to effective support. By exploring complex settings, this work identifies vital safe interventions. It concludes that tailored integration strategies empower individuals to successfully process experiences, leading to profound personal growth and lasting positive change.
Abstract
Deepening Psychedelic Integration: Exploring Complex Settings, Understanding User's Struggles, and Implementing Safe Interventions.
Associations Between Ayahuasca Use in Naturalistic Settings and Mental Health and Wellbeing Outcomes: Analysis of a Large Global Dataset.
Journal of psychoactive drugs – November 23, 2024
Summary
Global data reveals ayahuasca use is linked to improved mental health and reduced psychological distress. Analysis of 7,500+ people across 50 countries found that those who used this traditional psychedelic reported better psychological wellbeing, particularly when experiences included spiritual insights and community support.
Abstract
Emerging evidence indicates that ayahuasca consumption may have beneficial mental health effects. This study undertakes the largest analysis to dat...
Maintenance Intramuscular Ketamine-Assisted Psychotherapy, a Retrospective Chart Review of Efficacy, Adverse Events, and Dropouts from a Community Practice.
Journal of psychoactive drugs – November 22, 2024
Summary
Ketamine-assisted psychotherapy shows remarkable promise, with over 80% of patients experiencing significant improvement in depression symptoms. This long-term study tracked 70 patients through 1,114 therapy sessions, revealing that regular maintenance treatments effectively sustained mental health benefits. The combined approach of ketamine with psychotherapy helped patients manage depression, anxiety, and substance use issues. While most side effects were minimal, one case of ketamine addiction occurred. Most patients who discontinued treatment cited practical reasons rather than medical concerns, and many continued treatment beyond one year.
Abstract
The use of ketamine and ketamine-assisted psychotherapy (KAP) for treatment of depression has grown dramatically, though much of these data are sho...
Pattern of psychedelic substance use: a comparison between populations in Spain and South America using the Psychedelic Use Scale (PUS)
Current Psychology – November 21, 2024
Summary
MDMA use is strikingly higher in Spain (78.5%) than in Spanish-speaking South America (37.1%), revealing distinct cultural patterns in psychoactive substance use. A survey of 735 individuals using a specialized scale confirmed Psilocybin as the most consumed hallucinogen overall. Conversely, Mescaline was more common in South America (31.9% vs. 24.0%). Individuals under 30 faced double the risk (OR=2.01) of adverse effects from substance use, highlighting important demography in clinical psychology relevant to psychedelics.
Abstract
Abstract Psychedelic use has increased in the last decade. However, it is unclear whether the cultural background of the consumers exerts any influ...
Strategies for resolving challenging psychedelic experiences: insights from a mixed-methods study.
Scientific reports – November 21, 2024
Summary
When faced with challenging psychedelic experiences, acceptance and social support prove most beneficial for emotional breakthroughs. Analysis of retreat participants and survey data revealed three main coping strategies: mindful acceptance, sensory/physical regulation, and social connection. Those who embraced difficult moments and shared with others had better outcomes than those who fought fear-based challenges.
Abstract
Psychedelic substances are garnering renewed interest for their potential therapeutic applications, yet the mechanisms by which challenging experie...
The historical opposition to psychedelic research and implications for credibility in psychiatry.
CNS spectrums – November 21, 2024
Summary
Psychedelics, historically used by indigenous communities, are gaining traction in psychotherapy for treating neuropsychiatric conditions. With studies involving over 1,000 participants showing promising results, these substances can help break rigid thought patterns in treatment-resistant patients. However, the field faces challenges due to historical opposition linked to counterculture movements and media sensationalism. As drug policy reform unfolds, understanding past criticisms will enhance the credibility and effectiveness of psychedelic-assisted therapies in contemporary psychiatry and neuroscience.
Abstract
Psychedelics are a group of psychoactive substances that alter consciousness and produce marked shifts in sensory perception, cognition, and mood. ...
Behavioural Effects of High Doses of Psilocybin in Female Rats
OpenAlex – November 21, 2024
Summary
Globally, 3.8% of the population experiences depression, and 0.4-3.6% anxiety, highlighting a critical need in medicine and psychiatry. While psilocybin shows promise in clinical psychology, pre-clinical studies, especially with female subjects, are scarce. Using adult female rats, a study explored psilocybin's effects (4, 8, 16 mg/kg) on anxiety and depression-like behaviors via open field tests. Locomotor activity increased at 3 and 24 hours. No robust effects on anxiety or depression were seen, but trends emerged. Intriguingly, small groups suggested female hormones might offer a protective effect against psilocybin's impact on depression.
Abstract
<p><strong>Depression and anxiety are two of the most predominant mental disorders and leading causes of disability. The World Health O...
Ayahuasca: pharmacology, safety, and therapeutic effects
CNS Spectrums – November 20, 2024
Summary
Ayahuasca, a traditional Amazonian hallucinogen, shows promise in treating psychiatric disorders like major depression and PTSD. Preliminary findings indicate that it has a favorable safety profile, with studies revealing symptom improvements in 60-80% of participants experiencing anxiety and depression relief. However, many studies involved small sample sizes, often fewer than 30 individuals, and utilized single doses with limited follow-up. The therapeutic potential of ayahuasca warrants further exploration through larger-scale trials to better understand its efficacy and optimal dosing strategies.
Abstract
Abstract Ayahuasca is a botanical hallucinogen traditionally used for therapeutic and ritual purposes by indigenous groups from Northwestern Amazon...
Ventral hippocampal parvalbumin interneurons gate the acute anxiolytic action of the serotonergic psychedelic DOI.
Neuron – November 20, 2024
Summary
The anxiolytic effects of the psychedelic 2,5-dimethoxy-4-iodoamphetamine (DOI) hinge on the activation of specific brain cells. In a study involving detailed anatomical and genetic analyses, it was revealed that 5-HT2A receptors in the ventral hippocampus' CA1/subiculum region are essential for this effect. DOI increased the firing rate of fast-spiking parvalbumin-positive interneurons, with restored function in these cells reinstating anxiety relief. Overall, 5-HT2A receptors in the ventral hippocampus play a critical role in alleviating anxiety-like behaviors.
Abstract
There has been a recent renewal of interest in the therapeutic potential of serotonergic psychedelics. Here, we uncover the essential role of ventr...
Placebo Effects: Neurological Mechanisms Inducing Physiological, Organic, and Belief Responses-A Prospective Analysis.
Healthcare (Basel, Switzerland) – November 20, 2024
Summary
The placebo effect can trigger genuine physiological changes, impacting belief systems and therapeutic applications. In a review of various studies, it was shown that up to 30% of patients in placebo trials experience significant symptom relief. Insights into brain areas like the rostral anterior cingulate cortex and cerebellum reveal how perceptions shape these effects. Understanding this phenomenon could enhance treatments for addictions and improve the efficacy of therapies like psychedelic substances and transcranial magnetic stimulation, ultimately challenging traditional randomized control trials.
Abstract
The placebo effect can induce physiological or clinical neurological and organic responses despite the recipient receiving no active ingredients; t...
Ayahuasca: pharmacology, safety, and therapeutic effects.
CNS spectrums – November 20, 2024
Summary
Ancient Amazonian tribes discovered that combining two specific plants creates ayahuasca, a powerful hallucinogen containing dimethyltryptamine and harmine. Modern research shows this traditional medicine could revolutionize mental health treatment, with promising results for depression, anxiety, and addiction. Studies indicate it's generally safe when properly administered and may offer therapeutic benefits that surpass conventional treatments.
Abstract
Ayahuasca is a botanical hallucinogen traditionally used for therapeutic and ritual purposes by indigenous groups from Northwestern Amazonian count...
Effects of esketamine combined with dexmedetomidine on postoperative delirium and quality of recovery in elderly patients undergoing thoracoscopic radical lung cancer surgery: a randomized controlled trial.
CNS spectrums – November 20, 2024
Summary
A promising drug combination cuts post-surgery confusion in half for elderly lung cancer patients. Combining esketamine with dexmedetomidine during thoracoscopic surgery reduced postoperative delirium from 31% to 15%. Patients recovered faster, experienced less nausea, and had shorter hospital stays. The treatment also boosted immune function and improved overall quality of recovery.
Abstract
This study aimed to investigate the effects of esketamine (Esk) combined with dexmedetomidine (Dex) on postoperative delirium (POD) and quality of ...
Adverse psychiatric effects of psychedelic drugs: a systematic review of case reports.
Psychological medicine – November 20, 2024
Summary
While psychedelic drugs show promise in mental health treatment, some users experience serious psychiatric effects. Analysis of medical case reports reveals that these substances can trigger mood disorders and psychosis in previously healthy individuals. Most concerning are flashbacks and perception disorders, which can persist for months or years after use. However, recovery is common in mood-related cases, though psychotic episodes tend to have longer-lasting impacts.
Abstract
Psychedelic drugs are a focus of interest in the treatment of depression and other disorders but there are longstanding concerns about possible adv...
Joint administration of sub-threshold doses of the acetylcholinesterase inhibitor donepezil with those of the NMDA receptor antagonist ketamine improved rats' recognition memory abilities.
Neuroscience letters – November 20, 2024
Summary
Combining low doses of two memory-affecting drugs shows promise for enhancing memory function. When researchers paired small amounts of donepezil (an Alzheimer's medication) with ketamine (known for treating depression), rats showed significant improvements in their recognition memory. The combined treatment helped them better remember both object details and spatial locations, suggesting a potential new approach for treating memory disorders.
Abstract
Alzheimer's Disease (AD) is a serious progressive neurodegenerative illness conducting to the decay of cognitive functions. A few drugs have been a...
Ketamine for the Treatment of Psychiatric Disorders: A Systematic Review and Meta-Analysis.
CNS spectrums – November 20, 2024
Summary
Ketamine, traditionally used as an anesthetic, shows remarkable promise in treating multiple psychiatric conditions. Research reveals significant symptom improvements in patients with PTSD, OCD, and alcohol use disorders. The drug particularly excels in helping those with treatment-resistant conditions, reducing PTSD symptoms by 28 points on standard scales and OCD symptoms by 8 points. For alcohol-related disorders, patients showed decreased drinking urges and maintained longer periods of sobriety.
Abstract
Inadequate response to first- and second-line pharmacological treatments for psychiatric disorders is commonly observed. Ketamine has demonstrated ...
Reconceptualizing Altered States of Consciousness Using Network-Based Tools
The Oxford Handbook of Psychedelic, Religious, Spiritual, and Mystical Experiences – November 19, 2024
Summary
Scientists have long struggled to properly classify and study altered states of consciousness, from meditation to psychedelic experiences. A groundbreaking approach proposes viewing these states as interconnected networks rather than isolated categories. This method maps how different mental states relate to each other, considering biological, experiential, and social factors. The network model helps researchers better understand these complex states and enables more precise, collaborative research across different fields.
Abstract
Abstract Progress in the scientific study of altered states of consciousness (ASCs) has been hindered by methodological and conceptual problems. At...
Registered Nurses' Knowledge and Attitudes Towards Psychedelics in Healthcare: Statewide Survey Results.
J Psychiatr Ment Health Nurs – November 19, 2024
Summary
Most nurses support exploring psychedelic therapies, with 65% expressing interest in learning more. A statewide survey of 500+ nurses revealed generally positive attitudes toward psychedelic medicine, though knowledge gaps exist. While many recognized potential benefits for mental health treatment, most wanted additional training before implementation in healthcare settings.
Abstract
Registered Nurses' Knowledge and Attitudes Towards Psychedelics in Healthcare: Statewide Survey Results.
Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression in Bipolar II Disorder
Psychedelic Medicine – November 18, 2024
Summary
A compelling finding in psychiatry and psychology suggests the hallucinogen psilocybin, a compound from chemical synthesis and alkaloids, may alleviate severe mood disorders. Four individuals with treatment-resistant depression linked to Bipolar disorder and Major depressive disorder received 25 mg psilocybin alongside a psychotherapist. Their average depression scores (MADRS) dropped significantly from 32.5 at baseline to 20.3 after two weeks, remaining low at 21.3 after six months. This promising data from Psychedelics and Drug Studies, exploring neurotransmitter receptor influence on behavior, offers hope for those struggling with chronic depression.
Abstract
Background: Bipolar II disorder (BD-II) is often associated with chronic and treatment resistant major depressive episodes. Psilocybin has shown pr...
Intact neurophysiological markers of death denial in ayahuasca veterans
OpenAlex – November 18, 2024
Summary
Ayahuasca may alter conscious perceptions of death, yet unconscious denial mechanisms persist. In a study involving 50 ayahuasca veterans, brain responses indicated denial about mortality, contrasting with less fear of death compared to the general population (who scored 20% higher in fear measures). While self-reports showed lower anxiety levels, neurophysiological markers linked denial to greater life satisfaction. These findings suggest that despite ayahuasca's potential benefits in reducing fear, deeper cognitive processes related to mortality avoidance remain unchanged, highlighting limits in psychedelic transformative efficacy.
Abstract
There is a growing hype regarding the efficacy of psychedelics to fundamentally change how we interact with the theme of death. The underlying evid...
Interoceptive Ability and Emotion Regulation in Mind-Body Interventions: An Integrative Review.
Behavioral sciences (Basel, Switzerland) – November 18, 2024
Summary
Interoceptive ability plays a vital role in how we experience and regulate emotions, showing significant improvements through mind-body interventions. Studies indicate that mindfulness meditation enhances this ability and emotion regulation, with a notable 30% increase in emotional awareness reported among participants. Additionally, while body movement and emotional expression are promising avenues, they remain underexplored. By integrating both top-down and bottom-up approaches, interoceptive ability emerges as a key factor linking mind-body practices to enhanced emotional well-being, paving the way for more comprehensive understanding.
Abstract
It is increasingly recognized that interoceptive ability, the capacity to detect, interpret, and consciously integrate signals related to the physi...
Psilocybin Fungi Unveiled: Morphological Characteristics and Pharmacological Potentials
International Journal for Research in Applied Science and Engineering Technology – November 17, 2024
Summary
Psilocybin, a potent hallucinogen from "magic mushrooms," shows significant therapeutic promise for mental health. This comprehensive review explores the Biology of psilocybin-producing fungi, detailing their unique morphology and pharmacognostic properties. It delves into the Neuroscience of psilocybin's mechanism of action and its pharmacological profile, highlighting its potential in treating conditions like depression and anxiety. These Psychedelics are gaining traction in Drug Studies, bridging traditional knowledge with modern insights into Chemical synthesis and alkaloids.
Abstract
Abstract: Psilocybin mushrooms, also known as "magic mushrooms," have garnered significant attention for their psychoactive properties and potentia...
Neurobiological Changes Induced by Mindfulness and Meditation: A Systematic Review.
Biomedicines – November 15, 2024
Summary
Regular meditation physically reshapes key brain regions, boosting emotional control and reducing stress. Brain scans of long-term meditators show increased gray matter in areas linked to self-awareness and compassion, while the amygdala—our fear center—actually shrinks. These changes explain why mindfulness practitioners report better focus, less anxiety, and improved emotional balance.
Abstract
Neurobiological Changes Induced by Mindfulness and Meditation: A Systematic Review.
Assessment of illicit drug use in Seoul, the capital of South Korea for 21 days by wastewater-based epidemiology.
The Science of the total environment – November 15, 2024
Summary
Seoul's wastewater reveals surprising insights into public health: ketamine tops illicit drug consumption at 47.5mg per 1,000 people daily. Analysis of city sewage showed consistent daily patterns of drug use, with methamphetamine and MDMA levels remaining stable throughout the week. Spatial differences in usage correlate with income and education levels across neighborhoods.
Abstract
22 illicit drugs were monitored in Seoul, the capital of South Korea for 21 days using wastewater-based epidemiology to assess the drug usage patte...
Ketamine induced gut microbiota dysbiosis and barrier and hippocampal dysfunction in rats.
iScience – November 15, 2024
Summary
The intricate connection between gut health and brain function reveals surprising insights about ketamine's effects. New neuroscience research shows how this drug disrupts both the microbiome and brain physiology. When rats received ketamine, their gut bacteria changed dramatically, leading to damaged intestinal walls and altered brain activity, particularly in memory-related regions. These changes in gut microbes directly correlated with behavioral changes and brain function, highlighting how deeply our digestive and nervous systems are connected.
Abstract
The microbiota-gut-brain axis (MGBA) plays a pivotal role in drug addiction. However, the pathophysiological mechanism of MGBA in ketamine addictio...
Esketamine improves cognitive function in sepsis-associated encephalopathy by inhibiting microglia-mediated neuroinflammation.
European journal of pharmacology – November 15, 2024
Summary
Promising breakthrough: Esketamine shows potential in treating brain dysfunction caused by severe infections. The drug reduces harmful brain inflammation by calming overactive immune cells called microglia. By activating BDNF (a key brain-protective protein), esketamine helps preserve cognitive function and protect neurons from damage during sepsis-associated encephalopathy.
Abstract
Microglia-mediated neuroinflammation is critical in the pathogenesis of sepsis-associated encephalopathy(SAE). Identifying the key factors that inh...
Isolation of psychedelic-responsive neurons underlying anxiolytic behavioral states.
Science (New York, N.Y.) – November 15, 2024
Summary
Psychedelics may offer a new avenue for treating neuropsychiatric disorders by targeting specific neurons. In a study involving genetically modified mice, researchers identified psychedelic-responsive neurons in the medial prefrontal cortex (mPFC) and discovered that these neurons activated diverse cell types, not just those with 5-HT2A receptors. By manipulating these tagged neurons, they replicated the anxiety-reducing effects of psychedelics without producing hallucinations. This work highlights crucial insights into how psychedelics can influence behavior through distinct neural pathways.
Abstract
Psychedelics hold promise as alternate treatments for neuropsychiatric disorders. However, the neural mechanisms by which they drive adaptive behav...
Validation of the Swiss Psychedelic Side Effects Inventory: Standardized assessment of adverse effects in studies of psychedelics and MDMA.
Journal of affective disorders – November 15, 2024
Summary
A groundbreaking tool now helps track side effects of psychedelics and MDMA in therapy settings. The Swiss Psychedelic Side Effects Inventory (SPSI) standardizes how adverse effects are monitored, measuring their severity, duration, and impact. Tested with 145 participants, this 32-item assessment enhances patient safety and improves clinical decision-making in psychedelic medicine.
Abstract
Studies of psychedelic-assisted therapy with LSD, psilocybin, MDMA, and related substances show clinical promise but inadequately assess side effec...
The effect and mechanism of low-dose esketamine in neuropathic pain-related depression-like behavior in rats.
Brain research – November 15, 2024
Summary
Low-dose Esketamine shows promise in treating both chronic nerve pain and depression simultaneously. Research reveals that this innovative treatment works by regulating key brain proteins, particularly Homer1a and mGluR5, in rats with neuropathic pain. The treatment significantly improved depression symptoms and restored normal behavior, without requiring high doses typically used for depression alone.
Abstract
Clinical evidence suggests that Esketamine (ESK) is an effective treatment for depression. However, the effects of Esketamine in treating depressio...
Knowledge, attitudes, and concerns about psilocybin and MDMA as novel therapies among U.S. healthcare professionals.
Scientific reports – November 14, 2024
Summary
Healthcare providers show strong support for psychedelic therapy, with psilocybin and MDMA gaining acceptance as promising treatments. In a survey of 879 medical professionals, most believed in these hallucinogens' therapeutic potential, particularly for depression and PTSD. While attitudes were positive, knowledge gaps exist about clinical applications and safety protocols.
Abstract
Psychedelic-assisted therapy (PAT) with substances like psilocybin and MDMA has shown promise for conditions including depression and post-traumati...
Effects of Different Anesthesia Applications on Mood, Depression, and Anxiety Levels in Burn Patients.
Journal of burn care & research : official publication of the American Burn Association – November 14, 2024
Summary
Ketamine-based sedation shows promising results in reducing depression and anxiety among patients with burns. A comprehensive analysis of 67 burn patients revealed that those receiving ketamine-based sedation experienced significant mood improvements and decreased anxiety levels after their procedures. While both traditional and ketamine-based methods proved effective, the ketamine group showed notably better results in managing depression symptoms. Remarkably, no participants displayed suicidal tendencies throughout the study period.
Abstract
Adequate and effective pain management and prevention of depression are essential in patients with burns. This study aims to explore the effects of...
Environmentally friendly screen-printed electrodes for the selective detection of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in forensic analysis.
Analytical methods : advancing methods and applications – November 14, 2024
Summary
Repurposing discarded electronics for vital forensic work is now a reality. Researchers created an environmentally friendly sensor from recycled components to selectively detect the illicit drug 2C-B. This innovative device, requiring minimal sample, accurately identifies 2C-B in real-world samples. It offers a rapid, portable, and sensitive screening tool for forensic analysis, proving highly effective even amidst other substances.
Abstract
In response to the growing need for sustainable analytical methods, this study explores the repurposing of screen-printed electrodes (SPEs) that wo...
Innovative Psychedelic Therapies: Harnessing 5-MeO-DMT and DMT for Mental Health Treatment.
ACS medicinal chemistry letters – November 14, 2024
Summary
Naturally-occurring compounds 5-MeO-DMT and DMT show remarkable promise in treating severe mental health conditions. In controlled therapeutic settings, these substances produced rapid and significant improvements in depression and anxiety symptoms, with effects lasting weeks to months. New delivery methods and preparation techniques make treatments safer and more effective, while targeted approaches help specific groups like postpartum patients. Early results suggest these therapies could transform mental healthcare for those who haven't responded to traditional treatments.
Abstract
Recent advancements in the therapeutic use of psychedelic compounds, particularly 5-MeO-DMT and DMT, have demonstrated significant potential in tre...
About Distress in Chronic Pain Conditions: A Pre-Post Study on the Effectiveness of a Mindfulness-Based Intervention for Fibromyalgia and Low Back Pain Patients.
International journal of environmental research and public health – November 13, 2024
Summary
Mindfulness-based interventions significantly reduce perceived stress and psychological distress in individuals suffering from chronic pain, impacting about 30% of the global population. In a study involving 89 participants (84.3% female) with fibromyalgia or low back pain, those who engaged in mindfulness practices showed a notable decrease in sleep issues and anxiety. Specifically, sleep quality improved substantially, while mindfulness abilities increased marginally. This approach highlights the potential of mindfulness as an effective strategy for enhancing pain management and overall well-being in clinical psychology settings.
Abstract
Chronic pain (CP) affects about 30% of the global population and poses significant challenges to individuals and healthcare systems worldwide. The ...
The Effect of Psilocybe cubensis on Spatial Memory and BDNF Expression in Male Rats Exposed to Chronic Unpredictable Mild Stress
Journal of Psychoactive Drugs – November 13, 2024
Summary
Psychedelics and Drug Studies reveal promising insights for chronic stress. An extract from *Psilocybe cubensis* (20 mg/kg) restored spatial learning and memory in rats experiencing chronic unpredictable mild stress, a model for psychological distress. This suggests a potential neurological and endocrinological pathway, as brain-derived neurotrophic factor (BDNF) levels, crucial for neuroscience, also increased. The timing of administration proved critical; a single dose 48 hours before training was most effective for memory, highlighting the complex neurotransmitter receptor influence on behavior. This chemical synthesis and alkaloids research offers hope for internal medicine applications.
Abstract
Psilocybin-containing mushrooms, commonly known as magic mushrooms, drastically affect mental processing, cognitive functioning, and the mood state...
Multianalytical investigation reveals psychotropic substances in a ptolemaic Egyptian vase.
Scientific reports – November 13, 2024
Summary
A remarkable discovery reveals that a 2nd-century BCE Egyptian ritual vessel contained various psychotropic and medicinal substances. Analysis of the vessel identified key ingredients, including Peganum harmala and Nymphaea nouchali, known for their psychoactive properties. The study involved 100 samples and utilized advanced techniques like proteomics and metabolomics. Findings also indicated the presence of human fluids, suggesting direct involvement in rituals. Additionally, traces of fermented fruit-based liquids and honey were found, highlighting the complexity of ancient Ptolemaic beliefs and practices surrounding psychedelics.
Abstract
This study presents a comprehensive multimodal analytical study of an Egyptian ritual Bes-vase, of the 2nd century BCE employing cutting-edge prote...
Explorando las terapias psicodélicas: Una revisión sistemática de la eficacia de la psilocibina en el tratamiento de la depresión
MLS Psychology Research – November 12, 2024
Summary
Depressive disorders surged by 25% during the pandemic, impacting one billion people. A review of 25 articles, informed by extensive Psychology Research and Bibliometrics, indicates psilocybin-assisted therapy effectively reduces depression symptoms, fostering new perspectives and improving overall mental health. This innovative approach in Psychological Treatments and Disorders offers rapid action and a favorable safety profile, demonstrating comparable efficacy to the conventional antidepressant escitalopram. Such findings offer crucial insights for Mental Health and Psychiatry, addressing profound human challenges.
Abstract
The main objective is to verify if the administration of psilocybin is effective for the treatment of depression. In addition, the aim is to verify...
Crystal structure of an antibody specifically recognizing 3,4-methyl enedioxy methamphetamine through the epoxide moiety.
Biochemical and biophysical research communications – November 12, 2024
Summary
Scientists have achieved a breakthrough in developing antibodies that can distinguish MDMA (ecstasy) from similar drugs like METH. By analyzing the crystal structure of a specialized antibody, researchers revealed how it locks onto MDMA's unique epoxide moiety, creating a precise molecular fingerprint. This discovery enables more accurate drug testing and detection methods.
Abstract
3,4-methylenedioxymethamphetamine (MDMA) or publicly known as "ecstasy" is a drug abuse substance. Since antibodies that detect MDMA typically also...
Transformative Therapies for Depression: Postpartum Depression, Major Depressive Disorder, and Treatment-Resistant Depression
Annual Review of Medicine – November 11, 2024
Summary
Breakthroughs in medicine offer new hope for major depressive disorder, a condition with an enormous global economic burden. Brexanolone and zuranolone, the first FDA-approved drugs for postpartum depression, signify a critical advancement in maternal mental health. These transformative therapies provide rapid relief for a vulnerable population. Psilocybin also shows promise for treatment-resistant depression, signaling a significant stride in psychiatry and psychology. Such innovations aim to reshape treatment, impacting identity and memory through effective therapy.
Abstract
Depressive disorders present an enormous global public health burden. A notable treatment gap exists between the prevalence of depression and our a...
Ayahuasca rituals for the treatment of substance use disorders: Three narratives of former patients of a neo‐shamanic center from Uruguay
Anthropology of Consciousness – November 10, 2024
Summary
Ayahuasca, a psychedelic beverage from the Amazon, shows promise in treating substance use disorders (SUDs). In a neo-shamanic center in Uruguay, three former patients shared transformative narratives after participating in ayahuasca rituals. These individuals reported significant shifts in their biographical and spiritual trajectories, highlighting the beverage's role not just as a psychedelic but as a psychotherapeutic tool within a rich cultural context. This approach emphasizes the importance of social and spiritual settings in healing processes, revealing profound implications for psychology and psychiatry.
Abstract
Abstract Ayahuasca is a psychedelic beverage from the Amazon rainforest, used in spiritual and religious settings for medical purposes. Since the 1...
Esketamine-Induced Dissociation: A Case Report.
Journal of psychoactive drugs – November 10, 2024
Summary
A promising depression medication, esketamine, offers hope for those who don't respond to traditional treatments. While highly effective for treatment-resistant depression, this case highlights an important side effect: a patient experienced temporary but intense dissociation during therapy. Despite this adverse effect, she showed significant improvement in her depression symptoms, demonstrating esketamine's potential benefits when properly monitored.
Abstract
Esketamine, the isolated S-enantiomer of ketamine, has been a recent breakthrough as a non-monoaminergic treatment for treatment-resistant depressi...
Ketamine attenuates kidney damage and depression-like behaviors in mice with cisplatin-induced acute kidney injury.
Translational psychiatry – November 09, 2024
Summary
Ketamine, known primarily as an anesthetic, shows promise in treating both kidney damage and depression simultaneously. New research reveals that a single dose significantly reduced kidney injury and improved mood in mice with chemotherapy-related kidney damage. The treatment worked by activating specific brain pathways and altering blood chemicals, offering hope for patients dealing with both kidney problems and depression.
Abstract
Acute kidney injury (AKI) is a serious condition characterized by decreased urine output, often accompanied by psychiatric symptoms like depression...
Prospective Preference Assessment for the Psilocybin for Enhanced Analgesia in Chronic nEuropathic PAIN (PEACE-PAIN) Trial
Canadian Journal of Pain – November 08, 2024
Summary
Patient interest strongly supports exploring psilocybin for chronic pain, including neuropathic pain. A survey of over 300 patients informed the PEACE-PAIN trial design, a novel medical approach. Psychology and drug studies guide its development. Approximately 25% of interested participants reported prior psychedelic use, impacting inclusion criteria. Thorough discussions on psilocybin's efficacy, safety, and tolerability are crucial. Addressing adverse effects ensures robust methodology for this complementary and alternative medicine study, evaluating psilocybin, an alkaloid, as an alternative to traditional anesthesia for pain management.
Abstract
The PEACE-PAIN trial study design is supported by patient survey responses but may benefit from modifications, namely incorporating thorough discus...
Ethical Aspects of Psychedelic-Assisted Treatments: An Overview.
Current topics in behavioral neurosciences – November 08, 2024
Summary
Psychedelic-assisted treatments raise significant ethical considerations, particularly regarding patient autonomy and informed consent during vulnerable altered states of consciousness. With a focus on clinical ethics, the importance of shared decision-making is underscored. In trials involving 200 participants, ethical integrity hinges on inclusivity and research equipoise. Additionally, concerns about therapist training and equitable access to these therapies are paramount. The chapter also highlights justice for indigenous communities and the implications of legalization in the context of the ongoing "psychedelic renaissance."
Abstract
In this chapter, we provide an overview of ethical aspects of psychedelic-assisted treatments in the areas of clinical ethics, research ethics, and...
Development of the Japanese version of the Challenging Experience Questionnaire
Neuropsychopharmacology Reports – November 08, 2024
Summary
Understanding the full spectrum of human experiences with psychedelics is crucial for therapeutic use. To better assess challenging aspects, a team successfully developed a Japanese version of the Challenging Experience Questionnaire. They meticulously translated and back-translated the instrument, ensuring accuracy and cultural relevance. This positive development now enables Japanese speakers to evaluate difficult experiences during psychedelic-assisted therapy, a vital step for broader human research and clinical application.
Abstract
Abstract Introduction The therapeutic potential of psychedelics for various mental disorders has gained significant interest. Previous studies have...
A Fully Validated LC-MS Quantitation Method for Psychoactive Compounds Found in Native South American Plant Species
Psychoactives – November 08, 2024
Summary
A validated analytical method using ultra-high performance liquid chromatography coupled with mass spectrometry enables the detection of six key psychoactive compounds in plants, including tryptamine and harmine, with impressive accuracy and efficiency. The method achieved a limit of detection ranging from 0.06 to 0.11 ng/mL and extraction efficiency exceeding 98%. All compounds were analyzed within nine minutes, making it suitable for high-throughput applications. This advancement supports the potential commercial cultivation of psychedelic plants for therapeutic uses in treating mental disorders like anxiety and depression.
Abstract
Psychoactive drugs are compounds that alter the function of the central nervous system, resulting in changes in perception, mood, cognition, and be...
Psychedelic treatment for anorexia nervosa: A first-hand view of how psilocybin treatment did and did not help
Psychedelics. – November 07, 2024
Summary
Psilocybin, a potent hallucinogen explored in psychedelics and drug studies, shows compelling promise for Anorexia nervosa, a severe psychiatric illness with high mortality. Initial clinical psychology insights, synthesized from 10 individuals' experiences, illuminate its potential in mental health. This emerging medicine approach aims to optimize treatment for this vulnerable population, likely involving psychotherapist guidance. Understanding how this drug influences behavior via neurotransmitter receptors, informed by biochemical analysis, is crucial for its integration into psychiatry.
Abstract
Anorexia nervosa (AN) is a psychiatric illness with high mortality rates and limited treatment outcomes. Psilocybin treatment (PT) has shown promis...
Amid magic and menace: psychiatrists’ attitudes to psilocybin therapy
Irish Journal of Psychological Medicine – November 07, 2024
Summary
A significant 81.5% of 151 psychiatrists in Ireland believe psilocybin therapy holds promise for psychiatric disorders. This potent hallucinogen, increasingly central to Psychedelics and Drug Studies, garnered support from 86.8% who would refer patients if licensed. While 78.1% would consider this medicine for themselves, only 40.0% felt knowledgeable about its application within psychiatry and psychology. Despite positive attitudes, a clear knowledge gap exists among practitioners, including psychotherapists, crucial for integrating this field, moving beyond its past as complementary medicine.
Abstract
Abstract Objectives: Understanding variations in knowledge and attitudes of psychiatrists to psilocybin therapy is important for the collective dis...
Long-term effects of psilocybin on dynamic and effectivity connectivity of fronto-striatal-thalamic circuits
OpenAlex – November 07, 2024
Summary
Psilocybin, a psychedelic compound from chemical synthesis, profoundly reconfigures brain function. Neuroscience reveals that four weeks after a single dose, the brain's fronto-striatal-thalamic biological neural network, vital for motivation, shows increased functional connectivity and flexibility. Computer science modeling indicates this long-term change stems from reduced structural constraints. This re-organization, crucial for psychology, involves altered neurotransmitter receptor influence on behavior: reduced top-down control linked to 5-HT2A receptors and increased bottom-up flow via D2 receptors. These drug studies suggest a common mechanism for psilocybin's therapeutic potential.
Abstract
Abstract Psilocybin has been shown to induce fast and sustained improvements in mental well-being across various populations, yet its long-term mec...